2025 was the year many Gulf launch plans stopped treating the United Arab Emirates as a single market. Federal registration through the Ministry of Health and Prevention (MOHAP) remained the legal gateway, but volume followed emirate-level formularies, insurance rules, and hospital-group procurement in Dubai and Abu Dhabi. BioNixus keeps this page as the 2025 UAE healthcare trends archive — the URL is unchanged — and has rewritten the body so it is actually about the Emirates rather than a recycled GCC template. For the current commercial agenda, read UAE healthcare market trends 2026. Country fieldwork design sits on the healthcare market research hub and the UAE country research page.
Why 2025 still matters
Search demand for “UAE healthcare market trends 2025” did not disappear when the calendar flipped. Access teams still use 2025 as the baseline year for insurance coverage, medical-tourism mix, and dual-emirate listing sequences. BioNixus therefore keeps this slug live, refreshes the article on 31 August 2026, and uses it as the historical spoke next to the UAE healthcare market report (sizing) and the UAE healthcare market overview 2026 (hospital and sales landscape).
What 2025 was not: a Saudi analogue. SFDA registration and NUPCO tendering govern the Kingdom. They do not govern Dubai or Abu Dhabi. Any 2025 briefing that mixed those acronyms into a UAE narrative was describing the wrong country — which is why this page was rebuilt.
Triple-regulator access in practice
Three authorities shaped every 2025 launch calendar:
- MOHAP — federal drug and device registration, list-price approval, and post-marketing surveillance. Without MOHAP, nothing is legally on the market.
- Dubai Health Authority (DHA) — facility licensing, Dubai formulary and insurance rules (including the Essential Benefits Plan), and the private-hospital density that makes Dubai the commercial hub.
- Department of Health – Abu Dhabi (DOH) — Abu Dhabi formulary and insurance logic (including Thiqa for nationals), plus the SEHA public hospital network and Mubadala Health / Cleveland Clinic Abu Dhabi tertiary demand.
The operational consequence in 2025 was dual-pathway work: a MOHAP dossier plus separate DHA and DOH evidence packs. BioNixus documents that split in the Abu Dhabi DOH vs Dubai DHA formulary guide and the UAE market access strategy article. Research programmes that averaged “UAE physicians” without stratifying by emirate and sector produced forecasts that finance teams could not defend.
Insurance, private spend, and medical tourism
Mandatory health insurance across the seven emirates made 2025 a payer year, not only a hospital-capacity year. BioNixus sizes private-sector spend at roughly 65% of total UAE healthcare expenditure. That mix is why retailer and private-hospital channels each matter as much as government formularies, and why employer-plan tiers in Dubai and Abu Dhabi create different price-sensitivity profiles than a blended national average.
Medical tourism amplified the same concentration: the UAE attracted over 350,000 medical tourists in 2025. High-acuity oncology, cardiology, and elective specialty volume clustered in flagship centres rather than spreading evenly across emirates. For insight teams, that meant named-institution samples (Cleveland Clinic Abu Dhabi, Dubai Healthcare City, Mediclinic, Aster, NMC) beat anonymous “UAE hospital” cells.
Specialty demand that showed up in 2025
2025 did not invent UAE specialty demand, but it made the therapy mix visible in commercial plans. Oncology, diabetes, and immunology were already the three largest pharmaceutical therapy areas by value going into 2026. Biosimilar policy in Abu Dhabi (DOH’s 2024 biosimilar guidance taking effect in August 2024) started to change switching conversations in immunology and supportive care. Rare-disease and genomics programmes continued to pull high-cost therapies into a small diagnosed-and-funded pool rather than a prevalence-based forecast.
Those therapy-level numbers belong in dedicated reports — see the UAE healthcare market report and BioNixus therapy reports for oncology, immunology, biosimilars, and rare disease. This trends page only records the 2025 pattern: specialty value grew faster than primary-care volume, and it grew inside insurance and flagship-hospital gates.
What 2025 taught insight and access teams
- Do not collapse Dubai and Abu Dhabi. Formulary logic, insurance mix, and tertiary referral paths differ. Stratify samples and evidence packs.
- Sequence MOHAP, then DHA and DOH. Federal registration is necessary and not sufficient. Build listing calendars per emirate.
- Use claims and e-claims context, then ask what claims cannot answer. Dubai’s utilisation reporting is unusually rich for the region; primary research should target physician rationale, tumour-board influence, and pharmacy-and-therapeutics objections.
- Bilingual fieldwork is not optional. Arabic clinical idiom and English affiliate reporting need to live in the same instrument, not in a translation afterthought.
- Keep Saudi and UAE workstreams separate. SFDA/NUPCO evidence does not substitute for MOHAP/DHA/DOH evidence.
Those lessons are the brief BioNixus still uses when a 2026 tracker is calibrated against a 2025 baseline.
How BioNixus uses the 2025 record
BioNixus designs UAE programmes with shared governance and emirate-specific sampling: physician and payer interviews across DHA-licensed and DOH-licensed facilities, KOL maps that name SEHA and private groups separately, and access narratives that do not recycle Saudi tender language. Pair this archive with UAE healthcare market trends 2026, the top healthcare market research companies in the UAE 2026 listicle, and the pharmaceutical companies in the UAE directory. To scope fieldwork, contact BioNixus.





